Glutathione S-Transferase Gene Polymorphism as a Susceptibility Factor for Acute Myocardial Infarction and Smoking in the North Indian PopulationSingh N.a · Sinha N.a · Kumar S.a · Pandey C.M.b · Agrawal S.c
Departments of aCardiology, bBiostatistics and Health Informatics, and cMedical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: Glutathione S-transferase (GST) plays a key role in the detoxification of xenobiotic atherogens generated by smoking. We investigated whether functional GST gene polymorphism might be associated with acute myocardial infarction (AMI) and smoking. No such investigation has previously been conducted among North Indians. Methods: 230 patients with AMI and 300 healthy controls of North Indian ethnicity were enrolled in the study. GSTM1/T1/P1 gene polymorphisms were examined using restriction fragment length polymorphism. Results: When GST polymorphism was analyzed in patients with AMI, GSTM1 null genotype frequencies were 0.24 and 0.21 among cases with coronary artery disease and controls, respectively. The respective GSTT1 null genotype frequencies were 0.10 and 0.20 (p = 0.001). GSTP1 variant Val/Val allele frequencies were 0.02 and 0.07 with p = 0.03. After risk factor adjustment, only GSTP1Val/Val was found to be protective against disease. Considering the effect of GST (T1, M1, and P1) gene polymorphism on smoking, subjects were further divided into smokers and nonsmokers. However, GSTT1 null as well as GSTP Val/Val genotypes were protective only in nonsmokers (p = 0.01 and p = 0.04). Conclusions: A significant protective effect of GSTT1 null and GSTP1 Val genotype against disease was observed in patients with AMI although protection was limited to nonsmokers.
© 2011 S. Karger AG, Basel
- Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV-6–IV-19.
- Elsby R, Kitteringham NR, Goldring CE, et al: Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem 2003;278:22243–22249.
- Hayes JD, Strange RC: Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154–166.
- Zhong S, Howie AF, Ketterer B, et al: Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991;12:1533–1537.
- Bruhn C, Brockmoller J, Kerb R, Roots I, Borchert HH: Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Biochem Pharmacol1998;56:1189–1193.
- Penn A, Snyder CA: Butadiene inhalation accelerates arteriosclerotic plaque development in cockerels. Toxicology1996, 113:351–354.
- Tamer L, Ercan B, Camsari A, et al: Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease. Basic Res Cardiol2004; 99:223–229.
- Park JH, El Sohemy A, Cornelis MC, Kim HA, Kim SY, Bae SC: Glutathione S-transferase M1, T1, and P1 gene polymorphisms and carotid atherosclerosis in Korean patients with rheumatoid arthritis. Rheumatol Int 2004;24:157–163.
- Wilson HM, Grant PJ, Hardie LJ, Wild CP: Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000;14:791–796.
Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WB, Parl FF: Breast cancer CYP1A1, GSTM1 and GSTT1 polymorphism: evidence of a lack of association in Caucasians and African-Americans. CancerRes 1998;58:65–70.
- Wilson MH, Grant PJ, Kain K, Warner DP, Wild CP: Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S-transferase M1. Biomarkers2003;8:43–50.
Sayed R, Deeba F, Kaiser J: Role of GSTM1 gene polymorphism and its association with coronary artery disease. JCMR 2010;2:022–025.
- Girisha KM, Gilmour A, Mastana S, et al: T1 and M1 polymorphism in glutathione S-transferase gene and coronary artery disease in North Indian population. Indian J Med Sci 2004;58:520–526.
- Cheng SL, Yu CJ, Chen CJ, Yang PC: Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004;23:818–824.
Soo JK, Myeong GK, Kwo SK, Jung SS, Sung VY, Joo HC: Impact of glutathione S-Transferase M1 and T1 gene polymorphisms on the smoking-related coronary artery disease. JKMS 2008;23:365–372.
- Zhou C, Tang J, Wang M, et al: Relationship of GSTM1 and GSTT1 genetic variant and markers of oxidative stress and inflammation in smokers with coronary artery disease. J Nanjing Med Univ 2009;23:300–304.
- Pickett CB, Lu AY: Glutathione S-transferases gene structure, regulation, and biological function. Annu Rev Biochem 1989;58:743–764.
- Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases. Annu Rev Pharmacol Toxicol2005;45:51–88.
- Abu-Amero KK, Al-Boudari OM, Mohamed GH, et al: T null and M null genotypes of the glutathione S-transferase gene are risk factor for CAD independent of smoking. BMC Med Genet 2006;7:38.
- Mastin JP: Environmental cardiovascular disease. Cardiovasc Toxicol 2005;5:91–94.
- Sundberg K, Johansson AS, Stenberg G, et al: Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1–1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis1998;19:433–436.
- Li R, Boerwinkle E, Olshan AF, et al: Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis2000;149:451–462.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.